EUVIMEDEUVIMED entdecken
Crossref

Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease

Funda Erbasan, Tahir Saygın Öğüt, Melis Dilbil, Mine Nokay, Mustafa Ender Terzioğlu, Veli Yazısız

Medicina Clínica · 2024

DOI: 10.1016/j.medcli.2024.06.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Clínica, 2024. Verfasst von Funda Erbasan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey. Electronic address: fundaerb@yahoo…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Lung Diseases, Interstitial, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate the treatment modalities and their effects in primary Sjögren's syndrome (pSS) patients with interstitial lung disease (ILD). METHODS: In this chart review study, patients diagnosed with pSS-related ILD (pSS-ILD) between January 2004 and August 2022 were screened. Glucocorticoid use and administered disease-modifying antirheumatic drugs (DMARDs) were determined. The difference between forced vital capacity (FVC) and diffusion capacity of the lungs for carbon monoxide (DLCO) before and after treatment was evaluated. RESULTS: ILD was present in 44 of 609 patients (7.2%) diagnosed with pSS. In 27 patients included in the study, steroid usage was 81.5%. There was a statistically insignificant increase in FVC% (from 80.20±22.1 to 81.6±23.0) and a decrease in DLCO% (53.7±15.3-52.2±19.3) with DMARD treatment (p=0.434 and p=0.652, respectively). There was no significant difference between the treatment groups (azathioprine [AZA], mycophenolate mofetil [MMF], and rituximab [RTX]) in terms of the change in FVC% and DLCO% compared with baseline levels. The effect of treatment on FVC and DLCO was similar in UIP and NSIP patterns. CONCLUSIONS: AZA, MMF, and RTX have similar effects on pulmonary functions in pSS-ILD and provide disease stabilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeLung Diseases, InterstitialAntirheumatic AgentsHumansFemaleMiddle AgedMaleRetrospective StudiesAgedTreatment OutcomeAdultVital CapacityGlucocorticoidsMycophenolic Acid

Stichwörter der Autor:innen

Disease-modifying antirheumatic drugs (DMARDs)Enfermedad pulmonar intersticialFármacos antirreumáticos modificadores de la enfermedad (FAME)Interstitial lung diseaseSjögren's syndromeSíndrome de SjögrenTratamientoTreatment

Substanzen

Antirheumatic AgentsGlucocorticoidsMycophenolic Acid

Autor:innen und Institutionen

  • Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey. Electronic address: fundaerb@yahoo.com.
  • Department of Rheumatology, Antalya City Hospital, Antalya, Turkey.
  • Department of Rheumatology, Edirne Sultan 1, Murat State Hospital, Edirne, Turkey.
  • Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey.

Zitieren

APA

Erbasan, F., Öğüt, T. S., Dilbil, M., Nokay, M., Terzioğlu, M. E., & Yazısız, V. (2024). Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease. Medicina Clínica. https://doi.org/10.1016/j.medcli.2024.06.012

Vancouver

Erbasan F, Öğüt TS, Dilbil M, Nokay M, Terzioğlu ME, Yazısız V. Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease. Medicina Clínica. 2024. doi:10.1016/j.medcli.2024.06.012

BibTeX
@article{Erbasan2024,
  author = {Erbasan, Funda and Öğüt, Tahir Saygın and Dilbil, Melis and Nokay, Mine and Terzioğlu, Mustafa Ender and Yazısız, Veli},
  title = {Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease},
  journal = {Medicina Clínica},
  year = {2024},
  doi = {10.1016/j.medcli.2024.06.012}
}
Kostenlos starten →